🏥Enveda Raises $311M at $2B Valuation for AI-Found Drugs
TL;DR
AI drug discovery startup Enveda raised a $311M Series E at a $2B valuation, double its price a year ago. It mines plants and microbes for medicines and has candidates in human trials, including one aimed at keeping weight off after stopping GLP-1s.
AI drug discovery startup Enveda raised a $311M Series E at a $2B valuation, double its price a year ago. It mines plants and microbes for medicines and has candidates in human trials, including one aimed at keeping weight off after stopping GLP-1s.
Key Points
$311M Series E led by Catalio Capital Management, with Iconiq participating
Valuation hits $2B, roughly doubling in 12 months
Founded in 2019 by Viswa Colluru, an early Recursion Pharmaceuticals employee
Clinical candidates target severe skin conditions and post-GLP-1 weight maintenance
Why It Matters
No AI-discovered drug has won FDA approval yet, so investors are paying up for companies with molecules already in patients rather than platform promises.
Quick Facts
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.
Join 3,491 builders reading daily.